# A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

> **NCT02968108** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 45 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT02968108
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-18
- **Primary completion:** 2018-09-19
- **Final completion:** 2022-03-18
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968108, "A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02968108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*